As of 2025-09-15, the Intrinsic Value of Cardiol Therapeutics Inc (CRDL.TO) is -2.14 CAD. This CRDL.TO valuation is based on the model Peter Lynch Fair Value. With the current market price of 1.51 CAD, the upside of Cardiol Therapeutics Inc is -241.55%.
Based on its market price of 1.51 CAD and our intrinsic valuation, Cardiol Therapeutics Inc (CRDL.TO) is overvalued by 241.55%.
Note: result may not be accurate due to the invalid valuation result of Peter Lynch's fair value model.
| Range | Selected | Upside | |
| a | |||
| Fair Value | -2.14 - -2.14 | -2.14 | -241.55% |
| P/E | (3.01) - (4.20) | (3.51) | -332.1% |
| DDM - Stable | (4.00) - (15.04) | (9.52) | -730.7% |
| DDM - Multi | (0.67) - (1.99) | (1.01) | -166.7% |
| Market Cap (mil) | 126.40 |
| Beta | 2.15 |
| Outstanding shares (mil) | 83.71 |
| Enterprise Value (mil) | 103.26 |
| Market risk premium | 5.10% |
| Cost of Equity | 9.01% |
| Cost of Debt | 5.00% |
| WACC | 9.01% |